PhRMA dues fell almost $100 million as major drugmakers exited

Rachel Cohrs Zhang reports on the intersection of health policy and business in Washington. She covers Capitol Hill, lobbying, and federal agencies. Her primary areas of focus are the pharmaceutical and hospital industries. She is also the co-author of the free, twice-weekly D.C. Diagnosis newsletter.